Novel therapies for muscular dystrophy and other muscle wasting conditions

Bibliography

• STRAUB V, CAMPBELL KP: Muscular dystrophies and the dystrophin-glycoprotein complex. CUIT. Opin. Neurol (1997) 10:168–175.
   PubMed Web of Science ®Google Scholar
• •Reviews the role of DGC complex in a number of muscular dystrophies.
   Google Scholar
• LYNCH GS, RAFAEL JA, CHAMBERLAIN JS, FAULKNER JA: Contraction-induced injury to dystrophic skeletal muscle fibers: comparisons among control, mdx and transgenic mdx mice. Am. J. Physiol. (2000) 279:C1290–C1294.
   Google Scholar
• LYNCH GS, RAFAEL JA, HINKLE RT, COLE NM, CHAMBER-LAIN JS, FAULKNER JA: Contractile properties of diaphragm muscle segments from old mdx and old transgenic mdx mice. Am. J. Physiol. (1997) 272:C2063–C2068.
   Google Scholar
• PETROF BJ, SHRAGER JB, STEDMAN HH, KELLY AM, SWEENEY HL: Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA (1993) 90:3710–3714.
   PubMed Web of Science ®Google Scholar
• SKUK D, TREMBLAY JP: Progress in myoblast transplan-tation: a potential treatment of dystrophies. Micros. Res. Tech. (2000) 48:213–222.
   PubMed Web of Science ®Google Scholar
• •Good update on the recent developments in myoblast transfer therapies for DMD and related conditions.
   Google Scholar
• ANTOZZI C, CONALONIERI P, MANTEGAZZA R, DI DONATO S: Emerging treatments in myopathies. Eur. Neurol (1997) 38:222–229.
   PubMedGoogle Scholar
• TAWIL R: Outlook for therapy in the muscular dystro-phies. Seminars Neurol (1999) 19:81–86.
   PubMed Web of Science ®Google Scholar
• TOESCU V, EDWARDS RHT, JACKSON MJ: Treatment of Duchenne muscular dystrophy: history and future directions. Basic Appl. Myol. (1994) 4:217–226.
   Google Scholar
• URTIZBEREA JA: Therapies in muscular dystrophy: current concepts and future prospects. Eur. Neurol (2000) 43:127–132.
   PubMed Web of Science ®Google Scholar
• BARTON-DAVIS ER, CORDIER L, SHOTURMA DI, LELAND SE, SWEENEY HL: Arninoglycoside antibiotics restore dystrophin function to skeletal muscles of mdxmice. Clin. Invest. (1999) 104:375–381.
   Google Scholar
• AUSTIN L, BOWER JJ, BENNETT T et al.: leukemia inhibi-tory factor ameliorates muscle fibre degeneration in the mdx mouse. Muscle Nerve (2000) 23:1700–1705.
   PubMed Web of Science ®Google Scholar
• GREGOREVIC P, HAYES A, LYNCH GS, WILLIAMS DA: Structure and function of regenerating rat skeletal muscle following myotoxic injury and administration of leukemia inhibitory factor (LIF). Muscle Nerve (2000) 23:1586–1588.
   PubMedGoogle Scholar
• KUREK JB: AM424: history of a novel drug candidate. Clin. Exp. Pharm. Physic)]. (2000) 27:553–557.
   PubMed Web of Science ®Google Scholar
• LYNCH GS, CUFFE SA, PLANT DR, GREGROREVIC P: IGF-I treatment improves the functional properties of fast-and slow-twitch skeletal muscles from dystrophic mice. Neuromuscul. Disord. (2001) 11:260–268
   PubMed Web of Science ®Google Scholar
• ZDANOWICZ MM, TEICHBERG S, O'CONNOR M, MOYSE J,SLONIM AE. Metabolic and structural effects of insulin-like growth factor-I and high-protein diet on dystrophic hamster skeletal muscle. Proc. Soc. Exp. Biol. Med. (1997) 215:168–173.
   Google Scholar
• MALTIN CA, DELDAY MI, WATSON JS et al.: Clenbuterol, a 13-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin. Sci. (1993) 84:651–654.
   PubMed Web of Science ®Google Scholar
• LYNCH GS, HINKLE RT, FAULKNER JA: Power output ofskeletal muscles of control and mdx(dystrophic) mice after clenbuterol treatment. Exp. Physiol. (2000) . 85:294–298.
   Google Scholar
• LYNCH GS, HINKLE RT, FAULKNER JA: Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment. Neuromuscul. Disord. (2001). 11:191–195.
   Google Scholar
• LYNCH GS, HINKLE RT, FAULKNER JA: Year-long treatment with clenbuterol increases muscle mass but not force or power output of skeletal muscles of mice. Clin. Exp. Pharm. Physiol. (1999) 26:117–120.
   PubMedGoogle Scholar
• LYNCH GS: Beta agonists. In: Performing Enhancing Substances in Sport and Exercise. Bahrke M, Yesalis CE (Eds.), Human Kinetics, Champaign IL, USA (2001) In press.
   Google Scholar
• KISSEL JT, MCDERMOTT MP, NATARAJAN R et al.:. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology (1998) 50:1402–1406.
   PubMedGoogle Scholar
• DUNLOP J, ROSENZWEIG-LIPSON S: Therapeutic approaches to obesity. Exp. Opin. Ther. Patents (1998) 8:1683–1694.
   Web of Science ®Google Scholar
• PARTRIDGE TA, BEAUCHAMP JR, MORGAN JE: Conver-sion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature (1989) 337:176–179.
   PubMed Web of Science ®Google Scholar
• •Early study demonstrating the efficacy of myoblast transfer therapy in an animal model of DMD.
   Google Scholar
• QU Z, BALKIR L, VAN DEUTEKOM JCT, ROBBINS PD, PRUCHNIC R, HUARD J: Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol (1998) 142:1257–1267.
   PubMed Web of Science ®Google Scholar
• KARPATI G, AJDUKOVIC D, ARNOLD D et al: Myoblast transfer in Duchenne muscular dystrophy. Ann. Neurol (1993) 34:8–17.
   PubMed Web of Science ®Google Scholar
• MENDELL JR, KISSEL JT, AMATO AA et al.: Myoblast transfer in the treatment of Duch enn e's muscular dystrophy. New Engl. J. Med. (1995) 14:446–451.
   Google Scholar
• FAULKNER JA, BROOKS SV, DENNIS RG, LYNCH GS: The functional status of dystrophic muscles and functional recovery by skeletal muscles following myoblast transfer. Basic Appl. Myol. (1997) 7:257–264.
   Google Scholar
• GUSSONI E, BLAU HM, KUNKEL LM: The fate ofindividual myoblasts after transplantation into muscles of DMD patients. Nat. Med (1997) 3:970–977.
   PubMed Web of Science ®Google Scholar
• IRINTCHEV A, ROSENBLATT JD, CULLEN MJ, ZWEYER M,WERNIG A: Ectopic skeletal muscles derived from myoblasts implanted under the skin. J Cell Sci. (1998) 111:3287–3297.
   PubMed Web of Science ®Google Scholar
• SMYTHE GM, FAN Y, GROUNDS MD: Enhanced migration and fusion of donor myoblasts in dystrophic and normal host muscle. Muscle Nerve (2000) 23:560–574.
   PubMedGoogle Scholar
• CHANG PL, BOWIE KM: Development of engineered cells for implantation in gene therapy. Adv. Drug Deliv. Rev. (1998) 33:31–43.
   PubMedGoogle Scholar
• COSSU G, MAVILIO F: Myogenic stem cells for the therapy of primary myopathies: wishful thinking or therapeutic perspective? J. C/in. Invest. (2000) 105:1669–1674.
   PubMed Web of Science ®Google Scholar
• •Update on the development and progress of stem cell therapy for muscle wasting disorders.
   Google Scholar
• MILLER JB, SCHAEFER L, DOMINOV JA: Seeking muscle stem cells. Curr. Top. Dev. Biol. (1999) 43:191–219.
   PubMed Web of Science ®Google Scholar
• GUSSONI E, SONEOKA Y, STRICKLAND CD et al.: Dystro-phin expression in the mdx mouse restored by stem cell transplantation. Nature (1999) 401:390–394.
   PubMed Web of Science ®Google Scholar
• •Presents results on bone marrow transplantation studies in an animal model of DMD with partial restoration of dystro-phin expression in affected muscles.
   Google Scholar
• LEE JY, QU-PETERSON Z, CAO B, KIMURA S et al.: Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol. 150:1085-1099.
   Google Scholar
• TINSLEY JM, POTTER AC, PHELPS SR, FISHER R, TRICKETT JI, DAVIES KE: Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature (1996) 384:349–353.
   PubMed Web of Science ®Google Scholar
• •Describes how utrophin can replace dystrophin and prevent dystrophy in mdx mice.
   Google Scholar
• BITTNER RE, SCHOFER C, WEIPOLTSHAMMER K et al: Recruitment of bone marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. Anat. Eblyol. (1999) 1 9 9:391–396.
   Google Scholar
• FERRARI G, COSSU G, MAVILIO F: Muscle regenerationby bone marrow-derived myogenic progenitors. Science (1998) 279:1528–1530.
   PubMed Web of Science ®Google Scholar
• ROMANO G, PACILIO C, GIORDANO A: Gene transfer technology in therapy: Current applications and future goals. Stem Cells (1999) 17:191–202.
   PubMed Web of Science ®Google Scholar
• ROMANO G, MICHELI P, PACILIO C, GIORDANO A: latestdevelopments in gene transfer technology: achieve-ments, perspectives and controversies over therapeutic applications. Stem Cells (2000) 18:19–39.
   PubMed Web of Science ®Google Scholar
• •Update on gene transfer technology that identifies concerns over safety of gene therapy programmes.
   Google Scholar
• AKKARAJU GR, HUARD J, HOFFMAN EP et al.: Herpes simplex virus vector-mediated dystrophin gene transfer and expression in mdx mouse skeletal muscle. J. Gene Med. (1999) 1:280–289.
   PubMed Web of Science ®Google Scholar
• ASCADI G, LOCHMÜLLER H, JANI A et al.: Dystrophin expression in muscles of mdxmice after adenovirus-mediated in vivo gene transfer. Human Gene Ther. (1996) 7:129–140.
   PubMedGoogle Scholar
• HARTIGAN-O'CONNOR D, CHAMBERLAIN JS: Develop-ments in gene therapy for muscular dystrophy. Micros. Res. Tech. (2000) 48:223–238.
   Google Scholar
• HOWELL JC: Is there a future for gene therapy?Neuromuscul. Disord. (1999) 9:102–107.
   Google Scholar
• KARPATI G, GILBERT R, PETROF BJ, NALBANTOGLU J:Gene therapy research for Duchenne and Becker muscular dystrophies. CUIT. Opin. Neurol. (1997) 10:430–435.
   PubMedGoogle Scholar
• •Provides good overview of gene therapies for DMD and related conditions.
   Google Scholar
• YAMAMOTO K, YUASA K, MIYAGOE Y et al.: Immuneresponse to adenovirus-delivered antigens upreg-u-lates utrophin and results in mitigation of muscle pathology in mdx mice. Human Gene Ther. (2000) 11:669–680.
   PubMedGoogle Scholar
• YUASA K, MIYAGOE Y, YAMAMOTO K, NABESHIMA Y,DICKSON G, TAKEDA S: Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett. (1998) 425:329–336.
   PubMedGoogle Scholar
• HAUSER MA, CHAMBERLAIN JS: Progress towards genetherapy for Duchenne muscular dystrophy. J. Endocrin. (1996) 149:373–378.
   PubMedGoogle Scholar
• HAUSER MA, AMALFITANO A, KUMAR-SINGH R, HAUSCHKA SD, CHAMBERLAIN JS: Improved adenovir al vectors for gene therapy of Duchenne muscular dystrophy. Neuromuscul. Disord. (1997) 7:277–283.
   PubMedGoogle Scholar
• •Describes efforts to improve adenoviral vectors for gene therapy of DMD.
   Google Scholar
• HUARD J, KRISKY D, OLIGINO T et al.: Gene transfer to muscle using herpes simplex virus-based vectors. Neuromuscul. Disord. (1997) 7:299–313.
   PubMedGoogle Scholar
• •Describes work incorporating full-length dystrophin into new viral vectors.
   Google Scholar
• VAN DEUTEKOM JCT, FLOYD SS, BOOTH DK et al: Implications of maturation for viral gene delivery to skeletal muscle. Neuromuscul. Disord. (1998) 8:135–148.
   PubMedGoogle Scholar
• RAFAEL JA, TINSLEY JM, POTTER AC, DECONINCK AE,DAVIES KE: Skeletal muscle specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nature Gen. (1998) 19:79–82.
   PubMed Web of Science ®Google Scholar
• RAFAEL JA, BROWN SC: Dystrophin and utrophin:genetic analyses of their role in skeletal muscle. Micros. Res. Tech. (2000) 48:155–166.
   PubMedGoogle Scholar
• TINSLEY J, DECONINCK N, FISHER R et al: Expression offull-length utrophin prevents muscular dystrophy in mdxmice. Nat. Med (1998) 4:1441–1444.
   PubMed Web of Science ®Google Scholar
• NARITA S, YORIFUJI H: Centrally nucleated fibers(CNFs) compensate the fragility of myofibers in mdx mouse. NeuroRep. (1999) 10:3233–3235.
   PubMedGoogle Scholar
• RAFAEL JA, TOWNSEND ER, SQUIRE SE, POTTER AC, CHAMBERLAIN JS, DAVIES KE: Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. Human Mol. Gen. (2000) 9:1357–1367.
   PubMedGoogle Scholar
• HOLT KH, CAMPBELL KP: Assembly of the sarcoglycancomplex - insights for muscular dystrophy. J Chem. (1998) 273:34667–34670.
   Google Scholar
• HACK AA, GROH ME, MCNALLY EM: Sarcoglycans in muscular dystrophy. Micros. Res. Tech. (2000) 48:167–180.
   PubMed Web of Science ®Google Scholar
• LEBAKKEN CS, VENZKE DP, HRSTKA therefore et al: Sarcospan-deficient mice maintain normal muscle function. Mol. Cell. Bid (2000) 20:1669–1677.
   Google Scholar
• DUCLOS F, STRAUB V, MOORE SA et al.: Progressivemuscular dystrophy in a-sarcoglycan-deficient mice. J. Cell Biol. (1998) 142:1461–1471.
   PubMed Web of Science ®Google Scholar
• LIM LE, CAMPBELL KP: The sarcoglycan complex inlimb-girdle muscular dystrophy. CUIT. Opin. Neurol (1998) 11:443–452.
   PubMed Web of Science ®Google Scholar
• MCPHERRON AC, LAWLER AM, LEE SJ: Regulation ofskeletal muscle mass in mice by a new TGF-beta superfamily member. Nature (1997) 387:83–90.
   PubMed Web of Science ®Google Scholar
• MCPHERRON AC, LEE SJ: Double muscling in cattle dueto mutations in the myostatin gene. Proc. Natl. Acad. Sci. USA (1997) 94:12457–12461.
   PubMed Web of Science ®Google Scholar
• YASHIRO K, SAIJOH Y, SAKUMA R et al.: Distincttranscriptional regulation and phylogenetic divergence of human LEFTY- genes. Genes Cells (2000) 5:343–357.
   PubMedGoogle Scholar
• RANKIN CT, BUNTON T, LAWLER AM, LEE SJ: Regulationof left-right patterning in mice by growth/differentia-tion factor-I. Nat. Genetics (2000) 24:262–265.
   PubMedGoogle Scholar
• MCDONALD T, WANG RP, BAILEY W et al.: Identificationand cloning of an orphan G protein-coupled receptor of the glycoprotein hormone receptor subfamily. Biochem. Biophys. Res. Comm. (1998) 247:266–270.
   PubMedGoogle Scholar
• BOWEN DC, PARK JS, BODINE S et al.: localization andregulation of MuSK at the neuromuscular junction. Dev. Biol. (1998) 199:309–319.
   PubMedGoogle Scholar
• VALENZUELA DM, STITT TN, DISTEFANO PS et al.: Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction and after injury. Neuron (1995) 15:573–584.
   PubMed Web of Science ®Google Scholar
• FROMM L, BURDEN SJ: Synapse specific and n eur eg-ulin -in duced transcription requires an Ets site that binds GABP-a /GABP-I3. Genes Dev. (1998) 12:3074–3083.
   PubMedGoogle Scholar
• MALTIN CA, JONES P, MANTLE D: Effect of protease inhibitors and clenbuterol on the in vitro degradation of dystrophin by endogenous proteases in human skeletal muscle. Biosci. Rep. (1993) 13:159–167.
   PubMedGoogle Scholar
• MONCMAN CL, WANG K: Effects of thiol protease inhibitors on myoblast fusion and myofibril assembly in vitro. Cell Motil. Cytoskel (1998) 40:354–367.
   PubMedGoogle Scholar
• WANG KKW, YUEN PW: Calpain inhibition - an overview of its therapeutic potential. Trends Pharmacol. Sci. (1994) 15:412–419.
   PubMedGoogle Scholar
• BORNMAN L, POLLA BS, LOTZ BP, GERICKE GS: Expres-sion of heat shock stress proteins in Duchenne muscular dystrophy. Muscle Nerve (1995) 18:23–31.
   PubMedGoogle Scholar
• BORNMAN L, POLLA BS, GERICKE GS: Heat shock protein 90 and ubiquitin - developmental regulation during myogenesis. Muscle Nerve (1996) 19:574–580.
   PubMedGoogle Scholar
• DOU QP, NAM S: Pharmacological proteasome inhibi-tors and their therapeutic potential. Exp. Opin. Ther. Patents (2000) 10:1263–1272.
   Web of Science ®Google Scholar
• MORRIS GE: Nuclear proteins and cell death in inherited neuromuscular disease. Neuromuscul. Disord. (2000) 10:217–227.
   PubMedGoogle Scholar
• SANDRI M, CARRARO U: Apoptosis of skeletal muscles during development and disease. Int. J. Biochem. Cell Biol. (1999) 31:1373–1390.
   PubMed Web of Science ®Google Scholar
• SPENCER MJ, WALSH CM, DORSHKIND KA, RODRIGUEZEM, TIDBALL JG: Myonuclear apoptosis in dystrophic mdxmuscle occurs by perforin-mediated cytotoxicity. Clin. Invest. (1997) 99:2745–2751.
   Google Scholar
• OLIVE M, MARTINEZMATOS JA, MONTERO J, FERRER I: Apoptosis is not the mechanism of cell death of muscle fibers in human muscular dystrophies and inflamma-tory myopathies. Muscle Nerve (1997) 20:1328–1330.
   PubMedGoogle Scholar
• SANDRI M, MINETTI C, PEDEMONTE M, CARRARO U: Apoptotic myonuclei in human Duchenne muscular dystrophy. Lab. Invest. (1998) 78:1005–1016.
   PubMedGoogle Scholar
• MCARDLE A, MAGLARA A, APPLETON P, WATSON AJM,GRIERSON I, JACKSON MJ: Apoptosis in multinucleated skeletal muscle myotubes. Lab. Invest. (1999) 79:1069–1076.
   PubMedGoogle Scholar
• SMITH ME, HUGHES S: Effect of 13-endorphin anda-melanotropin on muscle wasting in mice. J. Neurol Sci. (1995) 129 (Suppl):127-130. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Ther. Patents (2001)11(4)
   Google Scholar
• KHAN S, SMITH ME: Effect of beta-endorphin on thecontractile responses in mouse skeletal muscle. Muscle Nerve (1995) 18:1250–1256.
   PubMedGoogle Scholar
• KHAN S, SMITH ME: Actions of 3-endorphin peptides onthe contractions of mouse diaphragm muscle. Peptides (1997) 18:87–92.
   PubMedGoogle Scholar
• BOSS 0, HAGEN T, LOWELL BB: Uncoupling proteins 2and 3 - Potential regulators of mitochondrial energy metabolism. Diabetes (2000) 49:143–156.
   PubMed Web of Science ®Google Scholar
• DULLOO AG, SAMEC S: Uncoupling proteins: do theyhave a role in body weight regulation? News Phhysiol. Sci. (2000) 15:313–318.
   Google Scholar
• BING C, BROWN M, KING P, COLLINS P, TISDALE MJ,WILLIAMS G: Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. Cancer Res. (2000) 60:2405–2410.
   PubMed Web of Science ®Google Scholar
• PIERRAT B, ITO M, HINZ W et al: Uncoupling proteins 2and 3 interact with members of the 14.3.3 family. Eur.J. Biochem. (2000) 267:2680–2687.
   PubMedGoogle Scholar
• CLAPHAM JC, ARCH JRS, CHAPMAN H et al: Mice overex-pressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature (2000) 4 06 :415–418.
   Google Scholar
• SLATER GJ, JENKINS D: Beta-hydroxy-beta-methylbutyr ate (IAMB) supplementation and the promotion of muscle growth and strength. Sports Med. (2000) 30:105–116.
   PubMed Web of Science ®Google Scholar
• CLARK RH, FELEKE G, DIN M etal.: Nutritional treatmentfor acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine and arginine: a randomized, double-blind, placebo-controlled study. J. Parenter. Enteral. Nutr. (2000) 24:133–139.
   Google Scholar
• NISSEN SL, ABUMRAD NN: Nutritional role of theleucine metabolite beta-hydroxy-beta-methylbutyrate (HMB).J. Nutr. Biochem. (1997) 8:300–311.
   Web of Science ®Google Scholar
• PANTON LB, RATHMACHER JA, BAIER S, NISSEN S: Nutritional supplementation of the leucine metabolite beta-hydr oxy-beta-methylbutyr ate (11111B) during resistance training. Nutrition (2000) 16:734–739.
   PubMed Web of Science ®Google Scholar
• GALLAGHER PM, CARRITHERS JA, GODARD MP, SCHULZE KE, TRAPPE SW: Beta-hydroxy-beta-methylbutyrate ingestion, Part I: effects on strength and fat free mass. Med. Sci. Sports Exerc. (2000) 32:2109–2115.
   PubMed Web of Science ®Google Scholar
• TERJUNG RL, CLARKSON P, EICHNER ER et al.: Thephysiological and health effects of oral creatine supplementation. Med. Sci. Sports Exerc. (20 0 0) 32:706–717.
   Google Scholar
• GUERRERO-ONTIVEROS ML, WALLIMANN T: Creatine supplementation in health and disease. Effects of chronic creatine ingestion in vivo- down-regulation of the expression of creatine transporter isoforms in skeletal muscle. Mol. CelL Biochem. (1998) 184 :427–437.
   Google Scholar
• MATTHEWS RT, YANG L, JENKINS BG et al: Neuroprotec-tive effects of creatine and cyclocreatine in animal models of Huntington's Disease. J Neurosci. (1998) 18:156–163.
   PubMed Web of Science ®Google Scholar
• PULIDO SM, PASSAQUIN AC, LEIJENDEKKER WJ, CHALLET C, WALLIMAN T, RCJEGG UT: Creatine supple-mentation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett. (1998) 439:357–362.
   PubMed Web of Science ®Google Scholar
• FELBER S, SKLADAL D, WYSS M, KREMSER C, KOLLER A,SPERL W: Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study. Neurol. Res. (2000) 22:145–150.
   PubMed Web of Science ®Google Scholar
• TARNOPOLSKY MA, ROY BD, MACDONALD JR: A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve (1997) 20:1502–1509.
   PubMed Web of Science ®Google Scholar
• WYSS M, FELBER S, SKLADAL D, KOLLER A, KREMSER C, SPERL W: The therapeutic potential of oral creatine supplementation in muscle disease. Med. Hypoth. (1998) 51:333–336.
   PubMedGoogle Scholar
• BERMON S, VENEMBRE P, SACHET C, VALOUR S, DOLISI C: Effects of creatine monohydrate ingestion in sedentary and weight-trained older adults. Acta Physiol. Scand (1998) 164:147–155.
   PubMedGoogle Scholar